GNPNAT1 (Glucosamine-Phosphate N-Acetyltransferase 1)

UALCAN, The Human Protein Atlas(HPA), the Cancer Cell Line Encyclopedia(CCLE), TIMER, and TISIDB were used to analyze its relationship with clinical characteristics, co-expressed genes, immune infiltration, correlation with immunomodulators.GNPNAT1-associated gene, CD40LG was used to build a risk model to evaluate immunotherapy outcomes of patients with LUAD.GNPNAT1 was upregulated in LUAD both at mRNA and protein level in tumor tissues. Based on CD40LG, a risk model could predict the prognosis and immunotherapy outcome of LUAD.GNPNAT1 was an independent prognostic factor for LUAD.Our results have identified a prognosis-related gene that is useful to evaluate immunotherapy outcomes of LUAD patients.The signature may have crucial clinical significance in predicting survival prognosis, and immune infiltration based on GNPNAT1 gene.

GNPNAT1 is overexpressed in lung adenocarcinoma and serves as an adverse prognostic biomarker. Its modulation of immune cell infiltration and engagement of the ERK/MAPK signaling cascade underscores its potential as both a prognostic indicator and therapeutic target in LUAD.

Comparison with three established LUAD prognostic signatures (Shedden, Soltis, and Song) within the TCGA network showed that our 8-gene signature had comparable or superior predictive power while maintaining concordance with existing signatures, some of which contain an order of magnitude more transcripts. Our findings suggest that novel gene signature holds promise for refining early-stage LUAD prognostic modeling and informing treatment strategies.

This hydrogel "awakened" dormant SACC cells, suppressing their tumorigenic potential and leading to their eradication through sustained paclitaxel release in vivo. This approach presents a new therapeutic strategy for eliminating dormant tumor cells and reducing the risk of post-therapy cancer relapse.

Our consistent results highlighted the important roles of plasma SMAD2 and CREB3L4 in the risk of prostate cancer. Further investigations on these proteins may reveal their potential in the prevention and treatment of prostate cancer.

Down-regulation of GNPNAT1 expression reduces the immune resistance of non-small cell lung cancer to radiotherapy and enhances susceptibility to NK cell cytotoxicity.

This study designed a risk model based on the eight mRNAsi-related genes for predicting LUAD prognosis. The model accurately predicted the prognosis and survival of LUAD patients, facilitating the assessment of the sensitivity of patients to immunotherapy and chemotherapy.

In conclusion, we have successfully developed a predictive model incorporating immune and metabolism-related genes, encompassing gene expression levels of CAT/CCL20/GPI/INSL4 NT5E/GSTA3/GNPNAT1. This comprehensive model not only enables the prognosis prediction for LUAD patients but also facilitates the prediction of their response to first-line chemotherapy drugs and immune checkpoint inhibitors, thus demonstrating its broad potential in clinical applications. However, our study still has limitations as it is based on TCGA and GEO databases with limited pathological characteristics of patients. Therefore, more practical and valuable factors are needed to predict efficacy. The crosstalk between metabolism and immunity remains to be explored. Finally, this study lacks experimental evidence for the underlying gene expression of prognosis and further research is required.

GNPNAT1 inhibition also activated PI3K/AKT signaling, promoting proliferation, and impaired cell adhesion by mislocalizing EphB6, enhancing migration via the RhoA pathway and promoting epithelial-to-mesenchymal transition. These findings suggest that HBP plays a critical role in regulating CRPC cell behavior, and targeting this pathway could provide a novel therapeutic approach.

Taken together, these data indicate that GNPNAT1 serves as a prognostic biomarker for LUAD patient. Additionally, GNPNAT1 is critical for promoting tumorigenesis and metastasis of LUAD cells and may be a potential therapeutic target for preventing LUAD metastasis.

The low-risk group also showed potential benefits from immunotherapy. Our study proposes a memory CD4+ T cell-associated gene risk model as a reliable prognostic biomarker for personalized treatment in LUAD patients.

Immunization infiltration analysis showed that high GNPNAT1 was negatively connected with 16 immunization infiltration cell types and positively connected with four immunization infiltration cell types. As a whole, our results indicated that GNPNAT1 might be a probable biomarker for diagnosis and prognosis in breast cancer.